Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 15,459 $ 17,010 $ 51,765 $ 46,137
General and administrative 5,904 5,179 17,869 16,936
Total operating expenses 21,363 22,189 69,634 63,073
Loss from operations (21,363) (22,189) (69,634) (63,073)
Other income (expense), net:        
Interest income 677 29 1,098 140
Interest expense (3,819) (522) (10,832) (522)
Total other income (expense), net (3,142) (493) (9,734) (382)
Net loss (24,505) (22,682) (79,368) (63,455)
Other comprehensive loss:        
Unrealized loss on marketable securities (133) (2) (561) (9)
Total other comprehensive loss (133) (2) (561) (9)
Comprehensive loss $ (24,638) $ (22,684) $ (79,929) $ (63,464)
Basic and diluted net loss per common share $ (0.28) $ (0.33) $ (0.9) $ (0.92)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share 87,804,272 69,022,937 87,803,388 68,985,112